Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real‐World Setting
Kimberly Maxfield(Southwestern Medical Center), Issam Zineh(United States Food and Drug Administration), Bernadette E. Johnson‐Williams(United States Food and Drug Administration), Lingshan Wang(United States Food and Drug Administration), Robert Powell(University of North Carolina at Chapel Hill), Daniel González(University of North Carolina at Chapel Hill), Lauren Milligan(United States Food and Drug Administration), Qi Liu(United States Food and Drug Administration), Yaning Wang(Yangzhou University), Hao Zhu(United States Food and Drug Administration), Rajanikanth Madabushi(United States Food and Drug Administration)
Cited by 23
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
|Clinical Pharmacology & Therapeutics|2007|243